TY -的AU - Ni,赵盟——吴,贝盟-杨,清盟——燕,丽江L AU - Liu长庆AU -肖,瑞安J PY - 2022 DA - 2022/3/9 TI -移动医疗干预提高用药依从性和冠心病患者的健康状况之间:随机对照试验乔- J地中海互联网Res SP - e27202六世- 24 - 3 KW - mHealth KW -药物依从性KW -冠心病KW -血压KW -中国KW -随机对照试验AB -背景:许多慢性疾病的治疗涉及长期药物治疗，但找到提高药物依从性以促进良好健康结果的有效方法是一项持续的挑战。心脏保护药物可预防冠心病患者有害凝块扩大、心血管症状和治疗效果差，如高血压和高脂血症无法控制。然而，心血管保护药物依从性差已被报道为冠心病患者的一个全球性健康问题，在中国尤其令人担忧。目的:本研究旨在评估移动健康(mHealth)干预的效果，使用2个移动应用程序来改善药物依从性和健康结果。方法:在位于中国成都的一所主要大学附属医疗中心进行了一项随机、安慰剂对照、两组平行研究。参与者是通过传单和卫生保健提供者推荐招募的。每个参与者被观察了90天，其中包括60天的移动健康干预期和30天的非干预随访期。研究协调员分别使用微信和Message Express发送教育材料和服药提醒。参与者使用微信来接收教育材料和提醒。 Participants in the control group only received educational materials. This study received ethics approval from the Duke Health Institutional Review Board (Pro00073395) on May 5, 2018, and was approved by West China Hospital (20170331180037). Recruitment began on May 20, 2018. The pilot phase of this study was registered on June 8, 2016, and the current, larger-scale study was retrospectively registered on January 11, 2021 (ClinicalTrials.gov). Results: We recruited 230 patients with coronary heart disease. Of these patients, 196 completed the baseline survey and received the intervention. The majority of participants were married (181/196, 92.4%), male (157/196, 80.1%), and lived in urban China (161/196, 82.1%). Participants’ average age was 61 years, and half were retired (103/191, 53.9%). More than half the participants (121/196, 61.7%) were prescribed at least 5 medications. The mean decrease in medication nonadherence score was statistically significant at both 60 days (t179=2.04, P=.04) and 90 days (t155=3.48, P<.001). Systolic blood pressure and diastolic blood pressure decreased in the experimental group but increased in the control group. The mean decrease in diastolic blood pressure was statistically significant at both 60 days (t160=2.07, P=.04) and 90 days (t164=2.21, P=.03). The mean decrease in systolic blood pressure was significantly different in the groups at 90 days (t165=3.12, P=.002). Conclusions: The proposed mHealth intervention can improve medication adherence and health outcomes, including systolic blood pressure and diastolic blood pressure. Trial Registration: ClinicalTrials.gov NCT02793830; https://clinicaltrials.gov/ct2/show/NCT02793830 and ClinicalTrials.gov NCT04703439; https://clinicaltrials.gov/ct2/show/NCT04703439 SN - 1438-8871 UR - //www.mybigtv.com/2022/3/e27202 UR - https://doi.org/10.2196/27202 UR - http://www.ncbi.nlm.nih.gov/pubmed/35262490 DO - 10.2196/27202 ID - info:doi/10.2196/27202 ER -